Screening strategies for pancreatic cancer
Abstract
The life incidence of pancreatic cancer is 1,3%, but the incidence and mortality rates are getting higher. The disease has a really poor prognosis, the 5 year survival rate is about 10-13%. Due to the high incidence rate and poor prognosis comes the question whether with screening can we improve the prognosis, and if yes, which patients and how should we screen?
References
Sung H, Ferlay J, Siegel RL és mtsai: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and ortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71: 209-249. https://doi.org/10.3322/caac.21660
Zhang Q, Zeng L, Chen Y és mtsai: Pancreatic Cancer Epidemiology, Detection, and Management. Gastroenterol ResPract 2016; 2016: 1-10. https://doi.org/10.1155/2016/8962321
Habbe N, Langer P, Sina-Frey M és mtsai: Familial Pancreatic Cancer Syndromes. Endocrinol Metab Clin North Am 2006; 35: 417-430. https://doi.org/10.1016/j.ecl.2006.02.016
Greer JB, Lynch HT, Brand RE: Hereditary pancreatic cancer: A clinical perspective. Best Pract Res Clin Gastroenterol 2009; 23: 159-170. https://doi.org/10.1016/j.bpg.2009.02.001
Salvatore T, Marfella R, Rizzo MR és mtsai: Pancreatic cancer and diabetes: A two-way relationship in the perspective of diabetologist. Int J Surgery 2015; 21 Suppl 1: S72-77. https://doi.org/10.1016/j.ijsu.2015.06.063
Illés D, Czakó L: A pancreascarcinoma korszerű kezelése. Central European Journal of Gastroenterology and Hepatology/Gasztroenterológiai és Hepatológiai Szemle 2016; 2: 176-82.
Lee J, Creanga-Marariu I, Németh J és mtsai: Association of Pancreatic Cancer with Acute Pancreatitis: A Systematic Review and Meta-Analysis. Clin. Transl. Gastroenterol 2026; 17. https://doi.org/10.14309/ctg.0000000000000927
Hussein T, Mátrai P, Vass V és mtsai: Onset of pancreatic cancer before and after acute pancreatitis: A multicenter longitudinal cohort study. Pancreatology 2025; 25, 29-34. https://doi.org/10.1016/j.pan.2025.07.325
Chari ST, Leibson CL, Rabe KG és mtsai: Pancreatic Cancer-Associated Diabetes Mellitus: Prevalence and Temporal Association With Diagnosis of Cancer. Gastroenterology 2008; 134: 95-101.
Mellenthin C, Balaban VD, Dugic A és mtsai: Risk Factors for Pancreatic Cancer in Patients with New-Onset Diabetes: A Systematic Review and Meta-Analysis. Cancers (Basel) 2022; 14: 4684. https://doi.org/10.3390/cancers14194684
Klatte DCF, Wallace MB, Löhr M és mtsai: Hereditary pancreatic cancer. Best Pract Res Clin Gastroenterol 2022; 58-59. 101783
Aslanian HR, Lee JH, Canto MI: AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review. Gastroenterology 2020; 159: 358-362 https://doi.org/10.1053/j.gastro.2020.03.088
Vilela A, Quingalahua E, Vargas A és mtsai: Global Prealence of Pancreatic Cystic Lesions in the General Population on Magnetic Resonance Imaging: A Systematic Review and Metaanalysis. Clin Gastroenterol Hepatol 2024; 22: 1798-1809.e6 https://doi.org/10.1016/j.cgh.2024.02.018
Moutinho-Ribeiro P, Macedo G, Melo SA: Pancreatic Cancer Diagnosis and Management: Has the Time Come to Prick the Bubble? Front Endocrinol (Lausanne) 2019; 9: 779. https://doi.org/10.3389/fendo.2018.00779
Singhi AD, Koay EJ, Chari ST és mtsai: Early Detection of Pancreatic Cancer: Opportunities and Challenges. Gastroenterology 2019; 156: 2024-2040. https://doi.org/10.1053/j.gastro.2019.01.259
Săftoiu A, Hassan C, Areia M és mtsai: Role of gastrointestinal endoscopy in the screening of digestive tract cancers in Europe: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy 2020; 12; 52: 293-304. https://doi.org/10.1055/a-1104-5245
Chari ST, Wu B, Lopez C és mtsai: Risk of Pancreatic Cancer in Glycemically Defined New-Onset Diabetes: A Prospective Cohort Study. Gastroenterology 2026; 170: 106-117. https://doi.org/10.1053/j.gastro.2025.06.025
Goggins M, Overbeek KA, Brand R és mtsai: Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 2020; 69: 7-17. https://doi.org/10.1136/gutjnl-2019-319352corr1
Khan S, Chari ST: ENDPAC model for defining a high-risk group for pancreatic cancer: Strengths, limitations and the way forward. Pancreatology 2025; 25: 1404-1406 https://doi.org/10.1016/j.pan.2025.11.007
Signoretti M, Bruno MJ, Zerboni G és mtsai: Results of surveillance in individuals at high‐risk of pancreatic cancer: A systematic review and meta‐analysis. United European Gastroenterol J 2018; 6: 489-499. https://doi.org/10.1177/2050640617752182
Corral JE, Mareth KF, Riegert-Johnson DL és mtsai: Diagnostic Yield From Screening Asymptomatic Individuals at High Risk for Pancreatic Cancer: A Meta-analysis of Cohort Studies. Clin Gastroenterol Hepatol 2019; 17: 41-53.
https://doi.org/10.1016/j.cgh.2018.04.065
Pouw RE, Barret M, Biermann K és mtsai: Endoscopic tissue sampling - Part 1: Upper gastrointestinal and hepatopancreatobiliary tracts. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2021; 53: 1174-1188. https://doi.org/10.1055/a-1611-5091
Dumonceau JM, Deprez P, Jenssen C és mtsai: Indications, results, and clinical impact of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - Updated January 2017. Endoscopy 2017; 49: 695-714. https://doi.org/10.1055/s-0043-109021
Săftoiu A, Vilmann P, Dietrich CF és mtsai: Quantitative contrast-enhanced harmonic EUS in differential diagnosis of focal pancreatic masses (with videos). Gastrointest Endosc 2015; 82: 59-69. https://doi.org/10.1016/j.gie.2014.11.040
European Study Group on Cystic Tumours of the Pancreas: European evidence-based guidelines on pancreatic cystic neoplasms. Gut 2018; 67: 789-804. https://doi.org/10.1136/gutjnl-2018-316027
Ohtsuka T, Fernandez-del Castillo C, Furukawa T és mtsai: International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas. Pancreatology 2024; 24: 255-270. https://doi.org/10.1016/j.pan.2023.12.009
Scarà S, Bottoni P, Scatena R: CA 19-9: Biochemical and Clinical Aspects. Adv Exp Med Biol 2015; 867: 247-260. https://doi.org/10.1007/978-94-017-7215-0_15
Tripathi S, Tabari A, Mansur A és mtsai: From Machine Learning to Patient Outcomes: A Comprehensive Review of AI in Pancreatic Cancer. Diagnostics 2024; 14: 174. https://doi.org/10.3390/diagnostics14020174
Klatte DCF, Boekestijn B, Wasser MNJM és mtsai: Pancreatic Cancer Surveillance in Carriers of a Germline CDKN2A Pathogenic Variant: Yield and Outcomes of a 20-Year Prospective Follow-Up. J Clin Oncol 2022; 40: 3267-3277. https://doi.org/10.1200/JCO.22.00194
Overbeek KA, Cahen DL, Kamps A és mtsai: Patient-reported burden of intensified surveillance and surgery in high-risk individuals under pancreatic cancer surveillance. Fam Cancer 2020; 19: 247-258. https://doi.org/10.1007/s10689-020-00171-8
Paiella S, Secchettin E, Lionetto G és mtsai: Surveillance of Individuals at High Risk of Developing Pancreatic Cancer. Ann Surg 2024; 279: 37-44. https://doi.org/10.1097/SLA.0000000000006094
Copyright (c) 2026 Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.
